Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
TAE Life Sciences has raised $40 million in series A funding and launched as a subsidiary of the nuclear fusion energy company TAE Technologies. TAE Life Sciences aims to commercialize a cancer radiation treatment called boron neutron capture therapy. In BNCT, boron-10 is administered to tumors, irradiated with a beam of neutrons, and broken down into charged particles that kill cancer cells. The concept was first tested in humans in the 1950s but was slow to take off. TAE says its accelerator-based technology will make neutrons for BNCT more accessible in hospitals.
This article has been sent to the following recipient: